ImmunityBio (IBRX) Non Operating Investment Income (2015 - 2026)
ImmunityBio (IBRX) posted quarterly Non Operating Investment Income of $2.3 million for Q1 2026, up 160.88% year-over-year from $887000.0 in Q1 2025, and up 0.7% quarter-over-quarter from $2.3 million in Q4 2025.
ImmunityBio (IBRX) Non Operating Investment Income (2015 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Non Operating Investment Income for 12 consecutive years, with $2.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Investment Income rose 160.88% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $7.8 million (up 35.9% YoY), while the FY2025 annual figure was $6.4 million, down 19.69% from the prior year.
- Non Operating Investment Income rose to $2.3 million in Q1 2026 per IBRX's latest filing, from $2.3 million in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $3.1 million in Q1 2024 and bottomed at -$3.8 million in Q4 2022.
- Historically, Non Operating Investment Income has averaged $866764.7 across 5 years, with a median of $1.2 million in 2025.
- Annual changes were most pronounced in 2022 — Non Operating Investment Income tumbled 916.95% — and 2024, when it jumped 5037.14%.
- ImmunityBio's Non Operating Investment Income stood at -$3.8 million in 2022, then jumped by 112.69% to $484000.0 in 2023, then surged by 145.25% to $1.2 million in 2024, then jumped by 93.6% to $2.3 million in 2025, then grew by 0.7% to $2.3 million in 2026.
- Business Quant data shows IBRX's Non Operating Investment Income at $2.3 million in Q1 2026, $2.3 million in Q4 2025, and $2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn | 3.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.16 Mn |
| Jun 30, 2026 | 3.16 Mn |
| Mar 31, 2026 | 2.31 Mn |
| Mar 31, 2026 | 2.31 Mn |
| Dec 31, 2025 | 2.30 Mn |
| Dec 31, 2025 | 2.30 Mn |
| Sep 30, 2025 | 2.07 Mn |
| Sep 30, 2025 | 2.07 Mn |
| Jun 30, 2025 | 1.15 Mn |
| Jun 30, 2025 | 1.15 Mn |
| Mar 31, 2025 | 887,000.00 |
| Mar 31, 2025 | 887,000.00 |
| Dec 31, 2024 | 1.19 Mn |
| Dec 31, 2024 | 1.19 Mn |
| Sep 30, 2024 | 1.80 Mn |
| Sep 30, 2024 | 1.80 Mn |
| Jun 30, 2024 | 1.89 Mn |
| Jun 30, 2024 | 1.89 Mn |
| Mar 31, 2024 | 3.10 Mn |
| Mar 31, 2024 | 3.10 Mn |